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The (R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl-boronic acid, bortezomib (BTZ), which
binds the 20S proteasome subunit and causes a large inhibition of its activity, is a peptidomimetic boronic drug mainly used
for the treatment of multiple myeloma. Commercial BTZ, stabilized as mannitol derivative, has been investigated under the
common conditions of the clinical use because it is suspected to be easily degradable in the region of its boronic moiety.
Commercial BTZ samples, reconstituted according to the reported commercial instructions and stored at 4◦C, were analyzed
by high-ﬁeld nuclear magnetic resonance spectroscopy in comparison with identical samples bubbled with air and argon,
respectively. All the samples remained unchanged for a week. After a month, the air ﬁlled samples showed the presence of
two main degradation products (6% of starting material), the N-(1-(1-hydroxy-3-methylbutylamino)-1-oxo-3-phenylpropan-
2-yl) pyrazine-2-carboxamide (BTZ1; 5%, determined from NMR integration) and the (S)-N-(1-(3-methylbutanamido)-1-oxo-
3-phenylpropan-2-yl)pyrazine-2-carboxamide (BTZ2; 1%, determined from NMR integration), identiﬁed on the basis of their
chemical and spectroscopic properties. The BTZ1 and BTZ2 ﬁnding suggests that, under the common condition of use and at
4◦C, commercial BTZ-mannitol is stable for a week, and that, in time, it undergoes slow oxidative deboronation which partially
inactivates the product. Low temperature and scarce contact with air decrease the degradation process.
Copyright © 2009 Adele Bolognese et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Bortezomib (BTZ)[ 1], the (R)-3-methyl-1-((S)-3-phenyl-2-
(pyrazine-2-carboxamido) propanamido)butylboronic acid,
(BTZ, Figure 1), is one of the most important members of a
newclassofdrugs,containingaboronicacidmoiety,eﬀective
on a wide group of tumors. At present, it is mainly used
for the treatment of multiple myeloma, a plasma cell tumor
which accounts for 10% of all blood system malignancies
[2, 3]. BTZ is a peptidomimetic compound, constituted
by a modiﬁed leucine-phenylalaninedipeptide, containing a
boronic acid at the C-terminal. It is able to interact with
proteasome, an intracellular apparatus which brakes down
damaged or unneeded proteins, inhibiting the proteolysis
action [4, 5].
As a boronic acid [6], BTZ shows high aﬃnity for
hard oxygen-containing nucleophiles according to the Lewis
hard-soft acid-base theory. Speciﬁcally, peptide boronates
are well-known inhibitors of serine proteases, forming a
serine-boronate tetrahedral transition state complex. BTZ,
active at subnanomolar concentrations (Ki 0.6nM), seems
to interact with the hydroxyl of a threonine present in
the active site of the N-terminal of the 20S β5 subunit
of the proteasome. Formation of a tetrahedral complex
(X) inhibits the chymotryptic proteolytic activity, totally
hampering proteasomal functions (Figure 2).2 Advances in Hematology
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Figure 1: (R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-
carboxamido)-propanamido)butylboronic acid.
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Figure 2: Formation of tetrahedric complex between the hydroxyl
groupofthreoninepresentonthe20S β5subunitoftheproteasome
and the boronic residue of BTZ. A water molecule is involved in the
mechanism of complex formation [6–8].
Generally, boronic acids are compounds characterized
by a vacant 2p orbital. This electron deﬁciency deter-
mines a chemical instability resulting in the formation
of tetrahedral boron adducts owing to the attack of
nucleophile agents, such as water, hydroxide, alkoxide, or
amines. At room temperature, stable cyclic esters with
saccharides are also formed through rapid and reversible
reactions. Moreover, the aminoalkylboronic acids, boron
analogues of common amino acids, as BTZ is, undergo
a spontaneous 1,3-rearrangement to give the homologated
amines, owing to the instability of free α-amino groups
possessing hydrogen substituents. These compounds yield
boric acids and alcohols by degradation and undergo
oxidative reactions which easily destroy the C–B bond longer
and weaker than the corresponding C–C bond. Figure 3
illustrates this characteristic reactivity (reactions a and b),
which is of some interest for BTZ chemical stability [9–
11].
The aim of this study is to explore the chemical sta-
bility of a commercial BTZ sample (Velcade) in its phar-
maceutical form (i.e., stocked as a sterile, lyophilized for-
mulation with mannitol as a bulking agent, in a glass
vial ﬁlled with nitrogen), after its reconstitution according
to the commercial reported instructions and stored at
4◦C.
2.MaterialsandMethods
BTZ is commercialized by Millennium Pharmaceuticals
(Mass, USA) in the US and Janssen-Cilag in Europe under
the trade name Velcade, and is administered as intravenous
bolus. The vials are reconstituted with 3.5mL of sterile
NaCl 0.9% to produce 1mg/mL of BTZ and 10mg/mL of
mannitol. The product information states that reconstituted
BTZisstablefor8hourswhenstoredat<25◦Candpr ot ect ed
from light, and for 3 hours in a syringe.
The samples of BTZ under investigation were recon-
stituted using a sterile NaCl 0.9% solution (in deuterated
water D2O, Merck) to produce the suitable NMR samples,
according to the commercial reported instructions.
Sample A was used for a direct NMR investigation
without further treatment, while the tubes containing the
samples B and C were ﬁlled with argon (B) and oxygen
(C), respectively. All the experiments were performed in
triplicate.
The solutions A, B, and C, kept in dark at 4◦C, were
subjected to 1H NMR investigation and tested during a week
to record possible diﬀerences in the mixture composition.
After one month, the previously examined samples A, B,
a n dC ,k e p ti nd a r ka t4 ◦C, were reanalyzed by 1HN M R
spectroscopy.
2.1. NMR and HPLC Experiments. Nuclear magnetic
resonance (NMR) spectra were recorded at 500MHz
for [1H] and 12MHz for 13C on a Fourier Transform NMR
Varian 500 Unity Inova spectrometer. Carbon multiplicity
was evidenced by DEPT experiments. HPLC analysis was
performed at room temperature (∼25◦C) using a Shimadzu
LC-6A pump equipped with Rheodyne 7215 injection
valve 20-mL, and a Shimadzu SPD-6A spectrophotometric
detectorworkingat280nm;aSymmetryC18Waterscolumn
was employed. The mobile phase consisted of 40%(v/v)
acetonitrile and 60%(v/v) 30mM KH2PO4H3PO4 (pH 3.0).
T h ep r o d u c tw a se l u t e da t3 . 9m i n u t e sw i t haﬂ o wr a t eo f
1mL/min.
3. Results and Discussion
Solutions A, B, and C, kept in the dark at 4◦C, tested at
intervals for a week by HPLC, did not diﬀer between the
initial and the ﬁnal stage (Figure 6(a)). After one month, a
small amount of two products eluted at 1 and 5 minutes
was recorded (Figure 6(b)). According to this evidence, no
change was observed in the NMR samples under the same
conditions. After one month at 4◦C, NMR reanalysis of
the same samples A, B, and C showed that A and B were
unchanged, whereas some modiﬁcations had taken place in
the spectrum of solution C.
Particularly, the proton (H, Figure 1) multiplet signal at
3.31δ attributed to the hydrogen on the carbon linked to
boron decreased in intensity by about 5%.
To investigate whether the origin of this diﬀerence was
due to the presence of oxidation decomposition products,
an air ﬂow was gently bubbled, for six hours, throughAdvances in Hematology 3
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Figure 3: Two possible degradation processes of BTZ in its pharmaceutical solution form (a) degradation pathway of boronic amino acids
in presence of water or other nucleophilic agents; (b) oxidative degradation pathway of boronic acids.
Table 1: Molecular weight, mass peak, and elemental analysis of BTZ,BTZ1,a n dBTZ2.
Comp.
Elemental analysis
MW Mass peak m/z CHN
calcd found calcd found calcd found
BTZ C19H25BN4O4 [M+H − H2O]
+ 59.39 59.48 6.56 6.58 14.58 14.61
384 367
BTZ1 C19H24N4O3 [M+H − H2O]
+
64.03 64.12 6.79 6.81 15.72 15.70
356 339
BTZ2 C19H22N4O3 [M+H]
+
64.39 64.32 6.26 6.30 15.81 15.78
354 355
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Figure 4: N-(1-(1-hydroxy-3-methylbutylamino)-1-oxo-3-
phenylpropan-2-yl) pyrazine-2-carboxamide (BTZ1).
a BTZ sample reconstituted according to the commercial
instructions and kept at 4◦C.
Themixturewasextractedwithchloroformandanalyzed
chromatographically by HPLC. Together with the main BTZ,
two new products, BTZ1 and BTZ2 (resp., ∼5% and 1%
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Figure 5: (S)-N-(1-(3-methylbutanamido)-1-oxo-3-
phenylpropan-2-yl)pyrazine-2-carboxamide (BTZ2).
of starting BTZ), were recovered and investigated by NMR
spectroscopy (see Figures 4 and 5). BTZ1 showed an 1H
NMR spectrum (CDCl3) with signals at δ 9.38 (1H, d;
J = 1.5Hz), 8.73 (1H, d; J = 2.6Hz), 8.48 (1H, m), 8.28 (1H,
bs), 8.02 (1H, bs), 7.26 (5H, m), 5.36 (1H, dd; J = 7, 5.54 Advances in Hematology
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Figure 6: HPLC analysis of bortezomib solutions A, B, and C kept in dark at 4◦C for a week. (a) No degradation product was observed. (b)
After a month, a small amount of two new products, eluted at 1 and 5 minutes, respectively, was recorded.
Hz),4.70(1H,dd;J = 5.1,9.0Hz),3.20(1H,dd;J = 14,5.1),
3.02 (1H, dd; J = 14, 9.1), 1.71 (1H, dd; J = 7, 14.4), 1.66
(1H, dd; J = 5.5, 14.4), 1.52 (1H, m), and 0.98 (6H, d). The
13C NMR spectrum showed signals at δ 171.3, 164.7, 148.5,
145.6, 144.7, 137.6, 135.9, 130.7 (2C), 129.1, 127.5 (2C),
74.4, 54.2, 43.6, 38, 24.1, and 22.4 (2C). The Mass spectra
of BTZ1 obtained from MALDI spectra recorded a peak
at 339m/e corresponding to the more stable protonated-
dehydrated ion, (M+ H −H2O, 100 %).
Onthebasisofthechemicalandspectroscopicproperties
[12–16], the product BTZ1 was identiﬁed as the N-(1-(1-
hydroxy-3-methylbutylamino)-1-oxo-3-phenylpropan-2-yl)
pyrazine-2-carboxamide. The decreasing intensity (about
5% in a month) of the signal at 3.31δ present in the
unchanged BTZ (H in Figure 1) recorded into the 1HN M R
spectrum represents a clear indication that a chemical
changing had happened at the carbon holding the hydrogen
corresponding to this signal.
Moreover, the reproducibility of the 1H NMR spectra
of samples A and B in time, clearly in contrast with the
degradation of sample C, suggests that the oxygen bubbled
into the C sample tube plays a determining role in the
BTZ stability. According to the chemical behavior of boronic
acid reported in literature, BTZ is sensitive to the oxidative
eﬀect of oxygen present in air and undergoes oxidative
deboronation to BTZ1.
Small amount (1% of starting BTZ) of another degrada-
tion product BTZ2, detected in the sample C, was recovered
and investigated by NMR spectroscopy. BTZ2 showed an
1H NMR spectrum (CDCl3) with signals at δ 9.38 (1H, d;
J = 1.5Hz), 8.73 (1H, d; J = 2.6Hz), 8.67 (1H, bs), 8.48
(1H, m), 8.02 (1H, bs), 7.28 (5H, m), 4.91 (1H, dd; J = 5.1,
9.1Hz), 3.18 (1H, dd; J = 14.0, 5.1), 3.12 (1H, dd; J = 14.0,
9.1), 2.09 (2H, m), 1.72 (1H, m), and 1.02 (6H, d). The
13C NMR spectrum showed signals at δ 172.1, 171.3, 164.7,
148.5, 145.6, 144.7, 137.6, 135.9, 131.7 (2C), 129.3, 127.8
(2C), 55.1, 46.3, 38, 25.1, and 22.5 (2C).
TheMassspectraof BTZ2 obtainedfromESandMALDI
spectra recorded a peak at 335m/e corresponding to the
protonated (M + H + 100%). Main characteristics of BTZ,
BTZ1,a n dBTZ2 are summarized in Table 1.
On the basis of the reported data, the structure of
N-(1-(3-methylbutanamido)-1-oxo-3-phenylpropan-2-
yl)pyrazine-2-carboxamide was attributed to BTZ2 [12–16].
Our results suggest that even after reconstitution with
saline, BTZ solutions are stable for at least one week in the
dark at 4◦C, and that very small amounts of BTZ derivatives
are detectable in vials stored in the presence of oxygen after
one month only. Thus, residual amounts of the drug in vials
used for therapeutic purposes can be stored and reutilized
within a few weeks, on the same patient or on diﬀerent ones,
without detectable loss of potency. These results may have
interesting implications, both for patient management and
i nt e r m so fc o s te ﬀectiveness, particularly for centers treating
small numbers of patients, considering the high cost of BTZ
therapy.
4. Conclusions
The BTZ compound present in a reconstituted sample of
Velcade kept at 4◦C in dark resulted stable for a week,
whereas it underwent oxidative transformation in presence
of high air (oxygen) concentration after a month. The
present result is not unexpected given the widely reported
lability of boronic acids toward the oxidative deboronation.
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